Literature DB >> 19561775

Matrix metalloproteinases and cardiovascular diseases.

A Papazafiropoulou1, N Tentolouris.   

Abstract

Matrix metalloproteinases (MMPs) are extracellular enzymes that are important in many physiologic and pathologic processes. Their activity is regulated mainly by tissue inhibitors of metalloproteinases (TIMPs). MMPs expression is related with the classical cardiovascular risk factors as well as with inflammation. They play a central role in atherosclerosis, plaque formation, platelet aggregation, acute coronary syndrome, restenosis, aortic aneurysms and peripheral vascular disease. Many studies have shown that commonly prescribed antihypertensive medications, glitazones and statins may influence MMPs activity. The aim of the review is to present literature data on the role of MMPs and their inhibitors in cardiovascular disease.

Entities:  

Keywords:  acute coronary syndromes; aneurysms; atherosclerosis; extracellular matrix; metalloproteinases

Year:  2009        PMID: 19561775      PMCID: PMC2683462     

Source DB:  PubMed          Journal:  Hippokratia        ISSN: 1108-4189            Impact factor:   0.471


  112 in total

1.  Release of gelatinase A during platelet activation mediates aggregation.

Authors:  G Sawicki; E Salas; J Murat; H Miszta-Lane; M W Radomski
Journal:  Nature       Date:  1997-04-10       Impact factor: 49.962

2.  Increased matrix metalloproteinase-9 activity in unstable carotid plaques. A potential role in acute plaque disruption.

Authors:  I M Loftus; A R Naylor; S Goodall; M Crowther; L Jones; P R Bell; M M Thompson
Journal:  Stroke       Date:  2000-01       Impact factor: 7.914

Review 3.  Polymorphism in matrix metalloproteinase gene promoters: implication in regulation of gene expression and susceptibility of various diseases.

Authors:  S Ye
Journal:  Matrix Biol       Date:  2000-12       Impact factor: 11.583

4.  Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.

Authors:  W C Duivenvoorden; H W Hirte; G Singh
Journal:  Clin Exp Metastasis       Date:  1999-02       Impact factor: 5.150

5.  Increased production of matrix metalloproteinases 1 and 3 by smooth muscle cells upon infection with Chlamydia pneumoniae.

Authors:  Jürgen Rödel; Dirk Prochnau; Katrin Prager; Evdokia Pentcheva; Matthias Hartmann; Eberhard Straube
Journal:  FEMS Immunol Med Microbiol       Date:  2003-09-22

6.  Release of matrix metalloproteinase-9 during balloon angioplasty in patients with stable angina. A preliminary study.

Authors:  Krzysztof Cedro; Anna Radomski; Marek W Radomski; Witold Ruźyłło; Krystyna Herbaczyńska-Cedro
Journal:  Int J Cardiol       Date:  2003-12       Impact factor: 4.164

7.  Relations of plasma total TIMP-1 levels to cardiovascular risk factors and echocardiographic measures: the Framingham heart study.

Authors:  Johan Sundström; Jane C Evans; Emelia J Benjamin; Daniel Levy; Martin G Larson; Douglas B Sawyer; Deborah A Siwik; Wilson S Colucci; Peter W F Wilson; Ramachandran S Vasan
Journal:  Eur Heart J       Date:  2004-09       Impact factor: 29.983

8.  Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases.

Authors:  Z S Galis; G K Sukhova; R Kranzhöfer; S Clark; P Libby
Journal:  Proc Natl Acad Sci U S A       Date:  1995-01-17       Impact factor: 11.205

9.  Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma.

Authors:  M Aikawa; E Rabkin; S J Voglic; H Shing; R Nagai; F J Schoen; P Libby
Journal:  Circ Res       Date:  1998-11-16       Impact factor: 17.367

10.  Serum matrix metalloproteinases MMP-2 and MMP-3 levels in dialysis patients vary independently of CRP and IL-6 levels.

Authors:  Gloria A Preston; Cheri V Barrett; David A Alcorta; Susan L Hogan; Lesley Dinwiddie; J Charles Jennette; Ronald J Falk
Journal:  Nephron       Date:  2002-12       Impact factor: 2.847

View more
  28 in total

Review 1.  The time has come to extend the expiration limit of cryopreserved allograft heart valves.

Authors:  Jan Burkert; Petra Kochová; Zbyněk Tonar; Robert Cimrman; Tereza Blassová; Ramadan Jashari; Radovan Fiala; Jaroslav Špatenka
Journal:  Cell Tissue Bank       Date:  2020-06-24       Impact factor: 1.522

2.  MMP9 inhibition increases autophagic flux in chronic heart failure.

Authors:  Shyam S Nandi; Kenichi Katsurada; Neeru M Sharma; Daniel R Anderson; Sushil K Mahata; Kaushik P Patel
Journal:  Am J Physiol Heart Circ Physiol       Date:  2020-10-16       Impact factor: 4.733

3.  Matrix metalloproteinase activity and glycosaminoglycans in chronic venous disease: the linkage among cell biology, pathology and translational research.

Authors:  Ferdinando Mannello; Joseph D Raffetto
Journal:  Am J Transl Res       Date:  2010-11-23       Impact factor: 4.060

Review 4.  Dietary natural products as epigenetic modifiers in aging-associated inflammation and disease.

Authors:  Levi W Evans; Matthew S Stratton; Bradley S Ferguson
Journal:  Nat Prod Rep       Date:  2020-01-29       Impact factor: 13.423

5.  MMP-9 drives the melanomagenic transcription program through histone H3 tail proteolysis.

Authors:  Yonghwan Shin; Sungmin Kim; Nikhil B Ghate; Suhn K Rhie; Woojin An
Journal:  Oncogene       Date:  2021-11-16       Impact factor: 9.867

Review 6.  Proteases in cardiometabolic diseases: Pathophysiology, molecular mechanisms and clinical applications.

Authors:  Yinan Hua; Sreejayan Nair
Journal:  Biochim Biophys Acta       Date:  2014-05-09

7.  Changes in Structural-Mechanical Properties and Degradability of Collagen during Aging-associated Modifications.

Authors:  Preety Panwar; Guillaume Lamour; Neil C W Mackenzie; Heejae Yang; Frank Ko; Hongbin Li; Dieter Brömme
Journal:  J Biol Chem       Date:  2015-07-29       Impact factor: 5.157

Review 8.  Matrix metalloproteinase-9: Many shades of function in cardiovascular disease.

Authors:  Andriy Yabluchanskiy; Yonggang Ma; Rugmani Padmanabhan Iyer; Michael E Hall; Merry L Lindsey
Journal:  Physiology (Bethesda)       Date:  2013-11

9.  Latest advances to enhance the therapeutic potential of mesenchymal stromal cells for the treatment of immune-mediated diseases.

Authors:  Angela Ceruso; Ainhoa Gonzalez-Pujana; Manoli Igartua; Edorta Santos-Vizcaino; Rosa Maria Hernandez
Journal:  Drug Deliv Transl Res       Date:  2021-02-25       Impact factor: 4.617

Review 10.  Matrix metalloproteinase-9 as a messenger in the cross talk between obstructive sleep apnea and comorbid systemic hypertension, cardiac remodeling, and ischemic stroke: a literature review.

Authors:  Saif Mashaqi; Heidi M Mansour; Hanan Alameddin; Daniel Combs; Salma Patel; Lauren Estep; Sairam Parthasarathy
Journal:  J Clin Sleep Med       Date:  2021-03-01       Impact factor: 4.062

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.